Merck & Co., Inc. vs TJX Companies Inc — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while TJX Companies Inc trades at $126.5 (market cap $141.81B). The key difference: Merck & Co., Inc. is far larger — about 2.6× TJX Companies Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | TJX | |
|---|---|---|
Market Cap | $366.28B | $141.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $168.41 |
52-Week Low | $77.60 | $126.10 |
Enterprise Value | $413.04B | $150.12B |
Dividend Yield | 2.29% | 1.49% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
TJX Companies (TJX) trades at $128.91, down 2.4% over 24 hours, with technical indicators showing bearish momentum but oversold RSI signals. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.22 exceeding expectations. Revenue grew to $56.36 billion in 2025, and net income margin improved to 9.73%. Analysts maintain a bullish consensus with 84.6% buy ratings and a $169 price target, citing expansion plans to 7,500 stores.
The outlook for TJX is positive due to consistent earnings outperformance and robust store growth strategy, though near-term stock pressure reflects valuation concerns and competitive comparisons. Key risks include market volatility and execution challenges in scaling operations. Investors may find opportunity in the current dip given strong fundamentals and analyst support.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →